Treatment of Apathy in Alzheimer's Disease With Modafinil

Completed · Phase 3 · Has a placebo group

Conditions studied: Apathy, Alzheimer's Disease

In brief

This study examined the effects of modafinil on apathetic symptomatology, performance of activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's disease (AD).

Key facts

Study ID

NCT01172145

Run by

Brown University

People needed

22

Starts

2005-07-01

Expected to finish

2007-09-01

Last updated by the study team

2011-03-04

Who can join

Age: 65 and older, up to 95. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• diagnosis of mild to moderate stage Probable Alzheimer's disease
• on a stable dose of a cholinesterase inhibitor medication for at least 30 days
• clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale

You may not qualify if…

• diagnosis of Major Depression
• focal brain lesion on neuroimaging
• history of significant substance abuse
• history of significant head trauma with loss if consciousness >10 minutes

Where it is running

• Butler Hospital — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.